Orforglipron dosage: the doses studied, and what the label actually covers

Orforglipron finally has an approved dose — sort of. In April 2026 the US FDA approved it for chronic weight management in adults with obesity, or overweight with a weight-related condition, under the brand name Foundayo — Eli Lilly's once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist, taken with no food or water restrictions.^[4] But the type 2 diabetes indication was still under review, not approved, as of this writing, and the specific milligrams most people ask about are the trial doses, not a number to copy at home. For what the molecule is and why the “non-peptide” part matters, start with our orforglipron oral GLP-1 evidence monograph; this page is about the doses and the titration behind those results.

The doses the trials used: once daily, up to 36 mg

The dose story runs across three trials. The Phase 2 type 2 diabetes study (26 weeks) tested a wide ladder — orforglipron at 3 mg, 12 mg, 24 mg, 36 mg or 45 mg once daily, taken with no food or water restrictions, against placebo and once-weekly dulaglutide; doses of 12 mg or greater produced the significant reductions in HbA1c and body weight.^[1] The Phase 3 program then narrowed the field. In early type 2 diabetes (ACHIEVE-1, 40 weeks), the once-daily doses were 3 mg, 12 mg and 36 mg, with weight loss of roughly −4.5%, −5.8% and −7.6% respectively.^[2] In obesity without diabetes (ATTAIN-1, 72 weeks), the once-daily doses were 6 mg, 12 mg and 36 mg, with weight loss of about −7.5%, −8.4% and −11.2%.^[3] Across both Phase 3 trials, 36 mg was the top dose tested and the most effective — the copper tread at the top of the illustration.

The part that matters most: slow escalation

The single most important dosing detail is what the trials did not do — they did not start anyone at 36 mg. Each arm began at a low dose and was stepped up over several weeks toward its assigned maintenance dose. The Phase 2 diabetes trial went as far as formally comparing two different dose-escalation regimens for its 36 mg and 45 mg cohorts, precisely to learn how the ramp affects tolerability.^[1] In both Phase 3 trials the pattern held: the most common adverse events were mild-to-moderate gastrointestinal effects, and they occurred mostly during dose escalation.^[2][3] The staircase above is the whole idea — you climb, you do not jump.

Why escalate slowly: the GI-tolerability rationale

Like every incretin drug, orforglipron's signature side effects are gastrointestinal — nausea, vomiting, diarrhea — and they concentrate in the titration window before the gut adapts.^[2]That is the same class behavior seen with the injectables. The distinctive convenience — a pill with no food or water rules — is exactly what sets it apart from the oral GLP-1 that came before it: semaglutide's tablet needs an absorption enhancer plus strict fasting-and-water timing, as covered in our oral semaglutide pioneer evidence. Removing those rules does not remove the need to titrate.^[1]

How the doses land against the injectables

Read against the top injectable agents, the magnitude is honest but not identical: roughly −11% at the 36 mg dose over 72 weeks in obesity^[3] sits below what the injectable semaglutide trials and the higher arms in the tirzepatide-versus-semaglutide comparison have shown. That is the expected trade-off for an orally manufacturable small molecule, and it matters most when weighed against the access advantage of a food-unrestricted pill. The dose that delivers it — 36 mg once daily, reached by slow titration — is a trial result, not a starting point.

The honest bottom line

Reduced to what the evidence supports: orforglipron was dosed once daily by mouth, with no food or water restrictions, escalated stepwise from a low start up to maintenance doses of 36 mg, with the slow ramp there specifically to limit gastrointestinal side effects.^[1][3] It now carries an FDA-approved weight-management indication in the United States,^[4] which makes the “dose” question less hypothetical than it is for a purely investigational drug — but the specific regimen is still a prescriber's call, tied to a label that has not finished evolving. The studied doses tell you the shape of the ladder; they are not an instruction to climb it on your own.